News

Blocking APOC1 protein can slow lymphoma cell growth
Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...
HealthDay on MSN13h
Dementia Biomarkers Associated With Age, Sex, APOE ε4 Status
Dementia biomarkers -- phosphorylated tau (P-tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) - ...
Early Alzheimer’s Clues Found in Adults as Young as 24
A new study reveals that cognitive changes tied to Alzheimer's risk factors begin far earlier in life than previously thought, some as early as age 24.
New Study Shakes Up Heart Disease Theory: High Cholesterol May Not Mean High Risk
A one-year prospective study found no correlation between atherosclerosis and extremely high cholesterol levels in 100 ...
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...
Leqembi®âˆ‡ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...
Pharmaceutical Technology on MSN6d
EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s
Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat ...
PharmiWeb6d
Leqembi® (lecanemab) is the First Medicine that…
Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...
Stop bad cholesterol entering your bloodstream by drinking heart-friendly milk
Oat milk is a nutritious alternative to dairy milk and may help reduce cholesterol levels thanks to its rich beta-glucan ...